Effect of LY3154207 on Cognition in Mild-to-Moderate Parkinson s Disease Dementia (PDD)

What we are studying

The purpose of this research study is to find out what effects (good and bad) LY3154207 has on a person and his/her condition (Parkinson's disease with dementia). The main reason for anyone to take part in this study is not to treat a condition but to help in answering the following research question: How does LY3154207 compare with placebo in treating memory and thinking problems in individuals with mild-to-moderate Parkinson’s disease dementia? LY3154207 is an investigational drug that is not approved by the FDA.

Who is Eligible

  • Genders:
    • Men
    • Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • Ages 40 - 85

Eligibility Criteria

  • *Must be diagnosed with Parkinson's disease with symptoms for at least 2 years *Diagnosed with dementia *No uncontrolled hypertension *Medications stable at least 4 weeks *Cannot have Deep Brain Stimulation (DBS)

What is involved

  • The study lasts 18 weeks. As part of the study you will undergo vitals
  • Blood draws
  • Ecgs (to check your heart)
  • Questionnaires
  • And memory tests.


You will received compensation for each visit completed.

Contact Information

Study Coordinator
Jessica Dimos
[email protected]
Principal Investigator
Mustafa Siddiqui, MD

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.